Kathryn Johnson Selected Research

Cytokines

1/2023

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathryn Johnson Research Topics

Disease

2	Primary Myelofibrosis (Myelosclerosis) 01/2023 - 12/2021
2	Crohn Disease (Crohn's Disease) 07/2010 - 12/2009
1	Polycythemia Vera 12/2021
1	Essential Thrombocythemia 12/2021
1	Infections 07/2016
1	Burns 07/2016
1	Wounds and Injuries (Trauma) 07/2016

Drug/Important Bio-Agent (IBA)

2	Infliximab (Remicade)FDA Link 07/2010 - 12/2009
1	CytokinesIBA 01/2023
1	ruxolitinibIBA 12/2021
1	pembrolizumabIBA 12/2021
1	ActicoatIBA 07/2016
1	SilverIBA 07/2016
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 07/2016
1	SodiumIBA 07/2016
1	Dihydrotachysterol (AT 10)IBA 07/2016
1	Carboxymethylcellulose Sodium (Polycell)FDA Link 07/2016
1	Polyethylene (Polythene)IBA 07/2016

Therapy/Procedure

1	Therapeutics 07/2010